Advances on timing of antiretroviral therapy for HIV infection

doi:10.3877/cma.j.issn.1674-1358.2016.02.002

Abstract

Abstract:

The decision about when to start antiretroviral treatment (ART) is among the most vexing issues in the field of HIV antiretroviral treatment. With more and more evidences accumulated, the international authoritative guides recently revised their stances on timing of ART in their guidelines for HIV-1-infected adults and adolescents. Early initiation of treatment is a major trend worldwide. This article reviewed the current researches for the early ART at home and abroad.

Key words: Acquired immunodeficiency syndrom, Antiretroviral therapy

Min Fang, Meihua Deng, Feili Liang. Advances on timing of antiretroviral therapy for HIV infection[J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2016, 10(02): 136-139.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-1358.2016.02.002

https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/Y2016/V10/I02/136

References 39

[1]	Wilkin TJ, Gulick RM. When to Start Antiretroviral Therapy?[J]. Clin Infec Dis,2008,47(12):1580-1586.
[2]	中华医学会感染病学分会艾滋病学组. 艾滋病诊疗指南第三版(2015版)[J]. 中华临床感染病杂志,2015,8(5):385-401.
[3]	Panel on Antiretroviral Guidelines For Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents [EB/OL]. 2016-3-25. URL
[4]	European AIDS Clinical Society. Guidelines version 8.0. October 2015[EB/OL]. 2015-10. URL
[5]	World Health Organization. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV[EB/OL]. 2015-9. URL
[6]	Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. a double-blind, placebo-controlled trial[J]. N Engl J Med,1987,317(4):185-191.
[7]	Volberding PA, Lagakos SW, Grimes JM, et al. The duration of zidovudine benefit in persons with asymptomatic HIV infection: prolonged evaluation of protocol 019 of the AIDS Clinical Trials Group[J]. JAMA,1994,272(6):437-442.
[8]	Concorde. MRC/ANRS randomized double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection[J]. Lancet,1994,343(8902):871-881.
[9]	Volberding PA, Lagakos SW, Grimes JM, et al. A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter[J]. N Engl J Med,1995,333(7):401-407.
[10]	Ho D. Time to hit HIV, early and hard[J]. N Engl J Med,1995,333(7):450-451.
[11]	Ricardo A Franco, Michael S Saag. When to start antiretroviral therapy: as soon as possible[J]. BMC Med,2013,11:147.
[12]	Cozzi Lepri A, Phillips AN, d’Arminio Monteforte A, et al. When to start highly active antiretroviral therapy in chronically HIVinfected patients: evidence from the ICONA study[J]. AIDS,2001,15(8):983-990.
[13]	Hirsch MS, Brun-Vezinet F, Clotet B, et al.Antiretroviral drug Resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel[J]. Clin Infect Dis,2003,37(1):113-128.
[14]	Mushy RL, da Silva BA, Hicks CB, et al. Seven-year efficacy of a iopinavir/dtonavir based regimen in antiretroviral naïve HIV-1-infected patients[J]. HIV Clin Trisis,2008,9(1):1-10.
[15]	中华医学会感染病学分会艾滋病学组. 艾滋病诊疗指南(2011版)[J]. 中华传染病学杂志,2011,29(10):629-640.
[16]	Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and HumanServices[EB/OL]. 2012-3-27. URL
[17]	European AIDS Clinical Society. Recommandations Version 7.01-November 2013 [EB/OL]. 2013-11. URL
[18]	When To Start Consortium. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies[J]. Lancet,2009,373(9672):1352-1363.
[19]	Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival[J]. N Engl J Med,2009,360(18):1815-1826.
[20]	Writing Committee for the CASCADE Collaboration. Timing of HAART initiation and clinical outcomes in human immunodeficiency virus type 1 seroconverters[J]. Arch Intern Med,2011,171(17):1560-1569.
[21]	Insight Start Study Group, Lundgern JD, Babiker AG, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection[J]. N Engl J Med,2015,373(9):795-807.
[22]	The Temprano Anrs 12136 Study Group. A trial of early antiretrovirals and isoniazid preventive therapy in Africa[J]. N Engl J Med,2015,373(9):808-822.
[23]	Couzin-Frankel J. Inflammation bares a dark side[J]. Science,2010,330(6011):1621.
[24]	Schouten J, Wit FW, Stolte IG, et al. Comorbidity and ageing in HIV-1 infection: the AGEhIV Cohort Study. XIX International AIDS Conference, 22-27 July 2012. Washington, DC, USA: JAIDS. 2012. Oral Abstract.
[25]	van Sighem A, Kesselring A, Gras L, et al. ATHENA National Observational Cohort: Risk of non-AIDS-defining events amongst HIV⁺patients not yet on ART. 20th Conference on Retroviruses and Opportunistic Infections, 3-6 March 2013. Atlanta, GA, USA: Congress on Retroviruses and Opportunistic Infections; 2013; Abstract 1042.
[26]	Strategies for Management of Antiretroviral Therapy (SMART) Study Group, Emery S, Neuhans JA, et al. Major clinical outcomes in antiretroviral therapy(ART)-naive participants and in those not receiving ART at baseline in the SMART study[J]. J Infect Dis,2008,197(8):1133-1144.
[27]	Baker JV, PengG, Rapkin J, et al. CD4⁺ cell count and risk of non-AIDS diseases foilowing initial treatment for HIV infection[J]. AIDS,2008,22(7):841-848.
[28]	Kelley CF, Kitchen CM, Hunt PW, et al. Incomplete peripheral CD4⁺ cell count restoration in HIV-infected patients receiving long-term antiretroviml treatment[J]. Chn Infect Dis,2009,48(6):787-794.
[29]	Gras L, Kesselring AM, Griffin JT, et al. CD4⁺ cell counts of 800 cells/mm³ or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm³ or greater[J]. J Acquir Immune Defic Syndr,2007,45(2):183-192.
[30]	Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy[J]. N Engl J Med,2011,365(6):493-505.
[31]	Worm SW, Sabin C, Weber R, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs(D:A:D) study[J]. J Infect Dis,2010,201(3):318-330.
[32]	Scherzer R, Estrella M, Li Y, et al. Association of tenofovir exposure with kidney disease risk in HIV infection[J]. AIDS,2012,26(7):867-875.
[33]	Bedimo R, Maalouf NM, Zhang S, et al. Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents[J]. AIDS,2012,26(7):825-831.
[34]	Kenedi CA, Goforth HW. A systematic review of the psychiatric side-effects of efavirenz[J]. AIDS Behav,2011,15(8):1803-1818.
[35]	UNAIDS. UNAIDS Report on the Global AIDS Epidemic 2012[EB/OL]. URL
[36]	Lundgren JD, Babiker AG, Gordin FM, et al. When to start antiretroviral therapy: the need for an evidence base during early HIV infection[J]. BMC Med,2013,11:148.
[37]	中华人民共和国国家卫生计生委办公厅. 国家卫生计生委办公厅关于修订艾滋病患者免费抗病毒治疗标准的通知.中国疾病预防控制中心性病艾滋病预防控制中心[EB/OL]. 2014-04-18. URL
[38]	联合国新闻中心. 联合国纪念世界艾滋病日.中国疾病预防控制中心性病艾滋病预防控制中心[EB/OL]. 2015-12-24. URL
[39]	李侠，楼金城，劳云飞, 等. 云南省HIV/AIDS病人早期抗病毒治疗的有效性和安全性分析[J]. 中国艾滋病性病,2014,20(3):165-168.

Please choose a citation manager

Content to export